Prokidney (PROK) Cash from Investing Activities (2021 - 2026)
Prokidney's (PROK) quarterly Cash from Investing Activities came in at $12.8 million in Q2 2026, down 31.02% year-over-year from $18.6 million in Q2 2025, and down 63.23% quarter-over-quarter from $34.8 million in Q1 2026.
Analysis
Prokidney (PROK) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Prokidney (PROK) has reported Cash from Investing Activities for 6 consecutive years, with $12.8 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash from Investing Activities fell 31.02% year-over-year to $12.8 million in Q2 2026; TTM through Jun 2026 was $104.7 million, a 631.67% increase from a year earlier, with the FY2025 full-year figure at $104.0 million, up 409.28% from the prior year.
- Cash from Investing Activities was $12.8 million for Q2 2026 at Prokidney, down from $34.8 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $58.4 million in Q1 2024 and troughed at -$192.6 million in Q1 2023.
- A 5-year average of -$8.9 million and a median of $6.3 million in 2022 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities tumbled 31221.57% in 2023 and soared 317.21% in 2024, its largest moves.
- Over 5 years, Cash from Investing Activities stood at -$306000.0 in 2022, then plunged by 31221.57% to -$95.8 million in 2023, then jumped by 115.73% to $15.1 million in 2024, then surged by 86.29% to $28.1 million in 2025, then sank by 54.42% to $12.8 million in 2026.
- The last three Cash from Investing Activities figures came in at $12.8 million (Q2 2026), $34.8 million (Q1 2026), and $28.1 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | -161.58 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | -55.66 Mn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | -74.05 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -120.00 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 53.26 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -9.88 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 26.69 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | -93.37 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | -2.82 Mn |
| 10 | Prokidney | 346.07 Mn | 346.07 Mn | - | 12.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.81 Mn |
| Mar 31, 2026 | 34.83 Mn |
| Dec 31, 2025 | 28.09 Mn |
| Sep 30, 2025 | 29.02 Mn |
| Jun 30, 2025 | 18.57 Mn |
| Mar 31, 2025 | 28.29 Mn |
| Dec 31, 2024 | 15.08 Mn |
| Sep 30, 2024 | -81.64 Mn |
| Jun 30, 2024 | 28.57 Mn |
| Mar 31, 2024 | 58.40 Mn |
| Dec 31, 2023 | -95.84 Mn |
| Sep 30, 2023 | -28.37 Mn |
| Jun 30, 2023 | -13.15 Mn |
| Mar 31, 2023 | -192.61 Mn |
| Dec 31, 2022 | -306,000.00 |
| Sep 30, 2022 | -207,000.00 |
| Jun 30, 2022 | -386,000.00 |
| Mar 31, 2022 | -839,000.00 |
| Dec 31, 2021 | -250.00 Mn |
| Sep 30, 2021 | -250.00 Mn |